Eli Lilly and Company (NYSE:LLY) Shares Acquired by Greenleaf Trust

Greenleaf Trust grew its holdings in Eli Lilly and Company (NYSE:LLY) by 21.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,034 shares of the company’s stock after acquiring an additional 5,210 shares during the quarter. Greenleaf Trust’s holdings in Eli Lilly and Company were worth $16,924,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $27,000. Retirement Group LLC lifted its holdings in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares during the period. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $35,000. Finally, Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $36,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on LLY shares. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. BMO Capital Markets lifted their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Finally, Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Price Performance

Shares of LLY traded down $19.64 during trading hours on Friday, hitting $726.31. 3,486,055 shares of the stock were exchanged, compared to its average volume of 3,073,465. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 12-month low of $369.76 and a 12-month high of $800.78. The company has a market cap of $690.11 billion, a price-to-earnings ratio of 125.67, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The stock’s 50-day moving average price is $764.24 and its two-hundred day moving average price is $658.28.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the business earned $2.09 earnings per share. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.